183 related articles for article (PubMed ID: 29789899)
1. [Review of clinical trials in retinopathy of prematurity : Current state and future perspectives].
Stahl A
Ophthalmologe; 2018 Jun; 115(6):456-463. PubMed ID: 29789899
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
3. [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].
Krohne TU; Müller A; Larsen PP; Holz FG
Ophthalmologe; 2018 Jun; 115(6):464-468. PubMed ID: 29654389
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
5. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
6. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
8. [Retinopathy of prematurity - therapy. Part 2].
Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
[TBL] [Abstract][Full Text] [Related]
9. Role of cytokines and treatment algorithms in retinopathy of prematurity.
Hartnett ME
Curr Opin Ophthalmol; 2017 May; 28(3):282-288. PubMed ID: 28141765
[TBL] [Abstract][Full Text] [Related]
10. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in Retinopathy of Prematurity : Concerns and adverse effects.
Sharma A; Shetty A; Reddy YCVG
Nepal J Ophthalmol; 2020 Jul; 12(24):298-307. PubMed ID: 33978625
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
Hartnett ME
Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
14. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
15. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
16. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
17. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
Patel JR; Ranjan SS; Wasserman BN
Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
19. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
[TBL] [Abstract][Full Text] [Related]
20. Management of retinopathy of prematurity.
Fleck BW
Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F454-6. PubMed ID: 23813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
